Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Shy of that 184 million, but not by much.
Fortunately, with 2 DED tests now entering the global market, and with a 6 months projected sales revenue up front, there should be no further need for notes or selling of treasury stock, so AXIM should settle in at about 185 million shares outstanding.
I heard somewhere (maybe it was in a dream), that Axim would need 200 doctors to sign onto their program (the 2 DED tests and the reader) in order to break even, and that anything above that would go towards profit. If that is true, and Axim signed up 100 from the previous conference, and potentially could do so at next week's conference, with who knows how many in-between, then Axim shouldn't need to sell anymore shares or to raise capital via notes.
Who knows, perhaps by mid 2023, Axim might be earning profits and focusing more on the cancer research (since Versea' certainly has the sales end of the company under control).
I believe that number is the shares issued. That 184 million doesn't change with note conversions.
It is the actual shares OUTSTANDING that changes, but very happy to see that this number has to be below 184 million.
I see AXIM as a billion dollar market cap company within 5 years, and @ 200 million shares outstanding, that would be $5 a share.
For someone averaged in at say 50 cents, that's 1000% in 5 years...not a bad return....
Actually, today was oddly a busy day.
146,000 shares at about $9.96, the 52 week high.
Average volume is under 4,000 shares a day.
That's almost $1.5 million.
Wish it meant something.....
I haven't been keeping track, and you seem to be on top of this, so I'm wondering: have all the notes been converted?
I would think if you held a note, the time to convert would be when AXIM is consistently at its lowest, which occurred a few weeks back. Now that AXIM has become what the shareholders were hoping for all along - a revenue generating company - its pps should begin to creep upward in the near future.
The next two known events to keep an eye out for (pun intended) are the optometrist convention at the end of this month, and the 3rd quarter 10-Q in the middle of the next, which, if we really want to wait, will of course reveal if there are any further notes remaining to be converted as well as the outstanding share count.
If you do want to do real, legitimate research, and not be the deliberate spreader of "misinformation" or "disinformation"'; you could reach out to the Transfer Agent to see who still owns what shares.
Standard Transfer Company
440 East 400 South
Suit 200
Salt Lake City, UT 84111
Phone: (801) 571-8844
Fax: (801) 328-4058
info@standardtransferco.com
https://standardtransferco.com/contact
There you will see who got stuck holding the bag with how many shares when the BLTA investment tanked in late 2018.
The saddest part is that the team at that time had a letter from a prospective investor (E.H. - with assets worth over $300 million in the Bahamas) pledging $80 million to finally make BLTA (or at that time, US Global Airways) a reality.
It is a shame that an article linking a Baltia investor and his personal issues put a damper on E.H. moving forward.
https://onemileatatime.com/baltia-hit-with-22-million-judgment-largest-shareholder-arrested/
Hey, Blue, did you ever find an updated OS?
I looked this morning but still see from August 15th, about 165 million.
I'm guessing now somewhere between 175 to 185 million, but can't seem to find any current data.
What's your find?
Its nice to see (hear about) the company making so many positive steps in the right direction. The exclusive agreement with Versea' being perhaps the biggest leap forward in Axim biotechnologies history.
I'm certain Versea' Ophthalmology division isn't just sitting around, waiting for the next conference in two weeks. Their sales staff is undoubtedly reaching out to attendees at the last conference, and cold calling others in the optometry industry. If nothing more, those calls are informing those who don't know about Axim's products to visit them at the next conference, and/or sending out literature and website information as well.
I think there is a lot going on behind the scenes, just not anything worthy of a PR, as what is going on is really "business as usual" for a firm - actively promoting sales of their products.
Actually, PRs right now only have the effect of raising the spirits of the current shareholders for a short period of time. New investors are waiting to see if there is any meat to go along with those potatoes, which will be seen in the 10-Q coming out in a little over 1 month.
Keep the faith.
It certainly looks like Axim has turned a corner and has overcome many of the setbacks that were so common during their growth phase just months ago.
I still see the competitive edge for AXIM.
Keep in mind, once an ophthalmologist signs onto AXIM's platform, and makes that initial $2,000 equipment purchase for the other two, already 510 (k) cleared tests, to add on the future MMP-9 test is just a simple purchase of each test kit ($7 - $10) and a programing of the reader (which is probably just going to be a free update).
The fact that AXIM's test is QUANTITATIVE makes AXIM's test "the better mousetrap."
Competition is not a bad thing.
A lot of times, competition can bring attention to the need for a product, and when you do it better, their efforts at introducing the product to the market and building public awareness can be viewed as free advertising for your own, superior product!
Furthermore, if all the insiders have now converted their notes into shares, and AXIM got a 6 month up front payment through its agreement with Versea', then this should really be the last group of shares to be added to shares outstanding.
I had counted on the liquidation to stop at around 200 million shares, but if this is the last conversion and AXIM doesn't need to sell more shares in order to cover expenses, then perhaps 175 to 180 million is a more accurate estimate at this time.
Still appears that everything within the company is moving in the right direction.
...can't wait to see the pps do likewise...
At this stage in the game, I certainly don't see the investor wanting to sell those shares.
This conversion is more along the lines of getting as many shares as possible for his $25,000.
The investor must have realized that AXIM had bottomed out and was on its way up, so the time to convert to get the most shares was now.
All positive signs, and I'm guessing everyone who had these notes should have already converted based on where AXIM is heading.
In other words, even the insiders see that AXIM bottomed out and is now on an upward trajectory.
So you feel that this conversion was calculated a couple of weeks ago but not consummated until recently (ie: within the last 4 days)?
I guess that is possible. Perhaps the individual wasn't able to sign the paperwork because of some pressing personal matters.
I wonder how many more of these are out there?
https://ih.advfn.com/stock-market/USOTC/axim-biotechnologies-qb-AXIM/stock-news/89250783/report-of-proposed-sale-of-securities-144?xref=newsalert
Looks to me like a $25,000 note was converted into 845,012 shares (just under 3 cents per share).
No doubt, and Axim has been Press Releasing its forward motion, but as you see with each PR, the pps may go up but then retreats back within a few days.
The current investors appreciate the PRs, but the "newbies" need more than just words. Newbies see the PRs along the lines of "the boy who cried wolf". I just think the newbies want to see validated dollars and cents.
I still think the next group of investors will arrive after the 10-Q, due out on Tuesday, 11/15, and if it is actually a positive or "uplifting" 10-Q, then I do not believe this one will be delayed.
If its good, I think we will see more interest in AXIM in the week's that follow its release..
Nice. It is all part of the "ramping up" stage, which really just began picking up steam less than a week ago.
For a while it seemed AXIM was one step forward, one step back. Then maybe 2 forward and one back. Now it seems like AXIM is on a nice jog forward with the occasional pause for a rest.
Axim just needs to catch the attention of new investors, which won't be of the high risk type (since those investors are already here).
The next group of investors, the next more cautious ones, will arrive after they see an SEC qualified 10-Q with positive revenue advancement.
I still believe that Axim has the ability to surpass its 52-week high (currently .51) before year-end.
I think EMERGENCY use authorizations are over for COVID.
I think the emergency is gone.
If AXIM wants to revive the Immunopass test for Nabs, then I think they are going to have to go through the normal channels, not fast track ot via an EUA.
Kind of wishing we knew how many attended the conference, how many visited the Versea/AXIM booth, how many signed up right away and how many requested more information etc.
It would give us a better idea of how this rollout went. Was the turnout and the results as expected, better, or worse than anticipated? Are there now follow up calls co.ing in with more individuals signing up for AXIM's diagnostic system?
I guess it will all pan out when the universe decides the time is right.
19,000 test kits for 100 readers is 1,900 kits per reader, or 950 tests of either of the two types, roughly speaking. A nice way to start off with AXIM's first exposure.
HOWEVER, I do point to these statements:
Good point. Since we are now exclusively partnered with Versea', anything the do in their other divisions can't hurt.
The products being marketed in Vegas appear to be "at home test kits", so the current DED line won't be marketed there and don't apply, but it would be interesting if Versea' and AXIM aren't now in talks about Immunopass?
The more I see, the more I like this exclusive relationship.
BTW, I believe Versea' is a private company? I would love to see someone try to take it public via a SPAC.....but that is another story altogether...
Trades so far today are all green, so it looks like the ask is getting slapped ( or should I say gently and lovingly caressed, since the volume just isn't there).
Almost 1/2 the day gone and just over 1/10th of the daily average shares have been traded.
The conference wraps up today.
I am not overly confident that we will be able to determine the success of the rollout by looking at AXIM's pps and volume over the next few days, so I am certainly hoping we get a PR later in the week with the results.
How many attended the conference, how many visited AXIM's booth, how many showed interest and how many signed up directly?
If we do get a PR, which I believe is a must, I'm certain we can deciphere how things went by the tone and the numbers.
It certainly look like AXIM's success is DIRECTLY tied to Versea's success with the Ophthalmic division.
I don't believe at this point that Axim could have found a better partner. Versea is ramping this up very nicely and PROFESSIONALLY.
This would not have happened except for the screw up by Empowered, and the lessons learned in that experience.
The universe (God) works in mysterious ways.
Agree 100%. If we can see the benefits of Axim's product line just by reading about it, imagine how impressive it must look with a live demonstration.
Ophthalmologists/doctors, especially those in private practice, are business men too, and they can see how Axim's products are going to revolutionize the industry and make their examinations so much simpler, cost effective, and more efficient.
Imagine the few who jumped on the opportunity on Friday, when they first saw it and had to make phone calls in order to get their trades in. Then imagine how the conference gets more packed on Saturday & Sunday, and Versea/Axim's booth is "the talk of the town."
I too believe Monday should be able to tell us how well Axim's product line did at the conference.
Then, keep in mind, there is another conference coming up a month later...
Lol, most profound PR in AXIM's history and the pps retracts by over 15%.
One big step for Axim Biotechnologies, one small step (hopefully upward) for AXIM pps.
Well, today is Thursday, so today is the day.
Nobody puts a PR out on a Friday - a complete waste of $.
If we don't see a PR today, then I doubt we will see any PR about the dollars received regarding the 1st payment on the contract and will just have to wait for the 10-Q (November 15).
There is, of course, the possibility of a post conference PR, especially if AXIM's testing system is extremely well received and Opthamologists actually sign on at the conference.
I'm roughly guessing that every 1 million in revenues will translate into an 8 cent increase in pps (not showing the math).
I'd take a PR like what I just did....give us the result (how much AXIM receives) without showing us how that number was derived.
Lol.....
Thank you, I put it out there to see how absolutely ridiculous that sounded, and you covered it nicely.
NO ONE would sign a 5 year contract with the most important part of and purpose for the contract.....the revenues it will generate...BLANK and to be filled in at a later date.
Clearly the contract had those numbers deliberately blanked out, so why are we assuming that a follow up PR is going to fill them in for us?
I agree the up front payment has to be a MATERIAL EVENT (actually, for AXIM at this point, ANY amount would be a material event), but maybe just disclosing the contract and how the revenues are to be determined.....and leaving the actual dollar figures blank.....is all that is required by the SEC!
To fill in the blanks might just be giving out too much information, like giving out TRADE SECRETS, and perhaps we won't see any PR or information about revenues until the 3rd quarter 10-Q.
...waiting for Christmas, and every time we think it has arrived, the date is moved further away.
Tomorrow, tomorrow.....you're always a day away.....
I am now thinking no PR this week, wait to see what the reception is like at the conference, and then based on what happens there, fill in all of the blanks and send the payment.
Perhaps we see a PR after the conference that tells us how the conference went AND fills in the blanks in the contract....
Curiosity is killing this cat. I am dying to see some of the blanks filled in (see below) for B-1 to B-3.
It is a HUGE contract, Global distribution, Exclusive, and with a term of 5 years.
Also, any new orders of product have to be paid, from 1.3 of the contract:
I'm under the impression that this distribution agreement works something along this line:
AXIM is manufacturing the kits. Versea' purchases an estimated 6 months worth of kits up front. If Versea sells those kits before the 6 months is up, then they will pre notify AXIM that they need more kits and purchase them outright.
I'm sure the manufacturer (AXIM) and the distributor (Versea') will be working very closely during this entire rollout and on into sales growth at least until sales hit a plateau and become more normalized and predictable.
BTW, just because a payment is due in 72 hours doesn't necessarily mean it gets paid in 72 hours. If the receiver gives a grace period for whatever reason, then the 4 day period to PR the transaction might not be predictable by us (what if AXIM gave Versea' a grace period until AFTER the conference in order to get a better idea of how well the kits will be received, and then better make a more accurate 6 month estimation of sales?).
I actually had to go to the SEC's Form 8k in order to find the 4 day reporting requirement.
The questions then become, how to translate 4 days AND is the $ amount Material.
Clearly the amount is material. 6 months of revenue for a company that hasn't had steady revenues EVER in its past....hell yes. And although in accounting terms, the revenues are FUTURE earnings, certainly the increase in the "cash on hand" account will be huge.
But how is 4 days calculated? Is it 96 straight hours and AFTER those hours expire, the first thing the next morning? Does it matter at WHAT TIME the agreement became effective? Is the 4 days translated as BUSINESS days, or effected by Holidays? Then again, what happens if the company actually reports slightly longer tha 4 days, are there exceptions allowed and what are the penalties?
I tried LIBERALLY take all that into consideration, and this morning appeared to me to be very generous.
In the long run, I don't think it makes all that much difference right now. I don't think another PR is going to move the needle any. AXIM needs to get its name out there, and the conference and the results of the conference are truly its first time to accomplish this.
A PR this week would be exciting and informative to those who know about ACIM, but I think the conference is going to expose AXIM to a bunch of new potential investors.
Here's hoping AXIM hits the ground running this coming weekend.
Looks to me like the agreement was signed on 9/15. The PR 9/19 was on time and payment should have been received on 9/19. If you want to exclude weekend hours, then payment should have been received on 9/21, or let's be generous and say 9/22. Since ANY payment to AXIM would dramatically change their balance sheet, this must be PR'd by 9/26, so let's say morning of 9/27...which is tomorrow.
So I think we should see this first thing tomorrow morning.
Do you think there will be any further big bath accounting going on this week?
I wonder if there is anything left to clean up?
The conference does start this Friday and ends on Monday (9/30 to 10/3).
Perhaps we may see a pre-conference PR highlighting important days and times over the weekend. Do you think John H will have an opportunity to speak and that AXIM might actually make a formal presentation?
Or maybe, AXIM might just fill in the blanks as to what the 6 month revenue projection is supposed to net them out before the end of the 3rd quarter.
Big "Bird" Bath accounting, but on a personal level.
AXIM is rolling things out in a very orderly manner. No second PR (following a Monday PR) last week, but 8 8ks (2 for each entity) substitutes for 1 PR in my book, especially when one understands the meaning behind these 8ks.
Clearly it was organized among the insiders to occur all at once, and to be released after close of business on Friday.
I'm fairly confident we will see some kind of a PR this coming week just prior to the conference.
Its similar to bow hunting, when you see your target and you slowly and deliberately load your arrow and pull back on the string.
I don't think AXIM is ready to release that arrow yet, but rather still has some more pulling to do, but they seem to be getting very close to that point (maybe just after the 2nd conference and around the time of the release of the 3rd quarter 10-Q?).
Its going to be an interesting next 6 months.
So what is this that we are looking at? What happened?
Unfortunately I am driving and can't fully appreciate what this says....
I am not near a computer but did anyone else get 4 alerts about a statement of change in beneficial ownership?
Interesting idea, I mean, after all, we do have all of those Immunopass test kits from the collapse of the agreement with Empowered that are just sitting around waiting to expire...
Oddly enough, I received an e-mail from Joysbio, Ltd. (see below). Did anyone else get such an email? They seem to be a competitor manufacture from China, but their lateral flow test kits are not in the DED line.
Here is there website:
https://en.joysbio.com/
And here is the email:
Dear Customer,
I hope everything goes well on your side. This is Rick from JOYSBIO Biotechnology Co., Ltd, a world-leading lateral flow assay manufacturer with a production capacity of 2 million tests per day. JOYSBIO sold over 200 million units of our SARS-COV-2 antigen rapid test kit in 2021 and was selected in multiple regional and national tenders. I'm writing to introduce our new Monkeypox antigen rapid test kit and other lateral flow assays. We offer a competitive price and fast delivery for orders of any size.
Similar to the widely used SARS-COV-2 antigen rapid test kit, the Monkeypox Antigen Rapid Test Kit is a rapid test cassette intended for the qualitative detection of monkeypox virus antigens from skin lesion exudate, acne scab swabs, or nasal swab specimens. It is CE-IVD certified for diagnostic use and is able to show a test result within 15 mins. More details and the product brochure is available on our website: https://en.joysbio.com/monkeypox-rapid-test-kit
Here is a list of other hot-selling products that we provide, a full list of our products is available on our website:
Monkeypox Antigen/Antibody Rapid Test Kit
SARS-COV-2 Antigen Rapid Test Kit (self-test and professional use)
SARS-COV-2 Neutralizing Antibody Rapid Test Kit
Influenza A/B + SARS-COV-2 Ag Rapid Test Kit
If you are interested in potential collaborations or any of our products, please don't hesitate to contact me for details. We look forward to hearing from you.
Best Regards,
Rick Zhang
Business Development Director
JOYSBIO Biotechnology CO., LTD.
E-mail: BD@JOYSBIO.com
Website: https://en.joysbio.com/
WhatsApp: +86-186-0545-0986
.09995 = 5 thousandths of a penny below 10 cents....